GoKawiil
Tech News
As Moderna and Merck develop personalized cancer therapies, data and diagnostics firm Tempus AI is emerging as a key infrastructure player supporting that work. Personalis, a genomic testing company, sits at the center of this positioning, suggesting a broader supply-chain opportunity beyond the drugmakers themselves.
Jim Cramer highlighted August as a recovery month for several S&P 500 stocks that had been beaten down by fears over AI disruption and slowing growth. Moderna topped the index after positive melanoma vaccine data with Merck, while enterprise software names like Palantir, Salesforce, ServiceNow and Veeva rebounded as earnings and product results eased investor doubts. Cramer noted that some of the earlier declines were worsened by a hedge fund, Situational Awareness, forced to unwind large bearish software bets in late July.
A phase III trial of intismeran, a personalized cancer vaccine developed by Merck and Moderna, showed that melanoma patients who received it had longer recurrence-free survival than those given a placebo. The double-blind study of more than 1,100 participants builds on an earlier phase II trial with 157 patients and moves the vaccine closer to regulatory approval.
Singer Dolly Parton has died at age 80, remembered for her philanthropic contributions to science alongside her music career. She provided early funding for Moderna's vaccine research and publicly received her own COVID-19 vaccination to counter public hesitancy, while her Imagination Library program continues distributing over three million books monthly to children worldwide.